NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Saturday, May 3, 2025 0:37

Description: Animalcare_UK_2SpotCol_RGB_vertical_Logo
Release 2.113
Pentoject 20% Injection
 
Species: Cats, Dogs, Mink, Small mammals
Therapeutic indication: Pharmaceuticals: Neurological preparations: Euthanasia products
Active ingredient: Pentobarbital Sodium
Product:Pentoject 20% Injection (100mL or 250mL bottles)
Product index: Pentoject 20% Injection
Incorporating:
Qualitative and quantitative composition
Each ml contains:
Active Substance(s)
Pentobarbitone Sodium
Excipients
Tartrazine 1409 (E102)
For the full list of excipients, see pharmaceutical particulars
Pharmaceutical form
Solution for injection.
A clear, yellow solution.
Clinical particulars
Target species
Dogs, cats, other small animals, and mink.
Indications for use, specifying the target species
Euthanasia in the target species.
Contraindications
Not for use in anaesthesia.
Special warnings for each target species
None.
Special precautions for use
i.Special precautions for use in animals
Use only for euthanasia.
ii.Special precautions for the person administering the veterinary medicinal product to animals
In the event of accidental self-administration, by injection or skin absorption, seek URGENT medical attention advising the medical services of barbiturate poisoning and show this advice. This is a potent drug which is toxic in man – particular care should be taken to avoid accidental ingestion and self-injection.
In the event of accident the following action should be taken:
Skin – Wash immediately with water and then thoroughly with soap and water. Eyes – Wash immediately with cold water and obtain medical advice.
Ingestion – Obtain medical attention immediately. Wash out mouth. Keep warm and rest.
Accidental self- injection – Obtain URGENT medical attention, advising medical services of barbiturate poisoning. Do not leave patient unattended.
Advice to Doctor – Maintain airways and give symptomatic and supportive treatment. This product is not sterile.
iii.Other precautions
None.
Adverse reactions (frequency and seriousness)
Body spasms may occur in some animals which may distress observers. Very low frequency when an appropriate dose is used and administered rapidly.
Use during pregnancy, lactation or lay
Not applicable.
Interaction with other medicinal products and other forms of interaction
Not applicable.
Amount(s) to be administered and administration route
To effect, usually 0.4 ml/kg in debilitated or elderly animals, or 0.6-0.8 ml/kg in younger or more fit animals. These dosages correspond to 80 mg/kg or 120-160 mg/kg, respectively. Preferably by rapid intravenous injection.
The intravenous route of administration should be the route of choice if possible but alternatives such as intraperitoneal or intramuscular are available when venepuncture is difficult to achieve (e.g. in cats). In some circumstances the intrathoracic route may be used but this is usually the last resort. There is a risk of injection into the lungs which causes coughing and distress. Direct injection into a chamber of the heart is rapid, but it may be difficult to accurately locate the heart chamber in larger dogs and repeated attempts could cause unnecessary pain and distress.
When it is predicted that euthanasia may be problematical (i.e. aggressive patients), it is recommended that premedication with an appropriate sedative be given.
Overdose (symptoms, emergency procedures, antidotes), if necessary
If accidentally administered to an animal not presented for euthanasia, care should be aimed at supporting the respiratory and cardiovascular systems. Use of artificial respiration, oxygen and analeptics are appropriate.
Withdrawal period(s)
Not for use in animals intended for human or animal consumption.
Pharmacological particulars
Pharmacotherapeutic group:
Barbiturates ATC Vet Code: QN51AA01
Pharmacodynamic properties
Pentobarbitone Sodium is a barbiturate. Injection of lethal doses causes progressive depression of the central nervous system, which may be considered as passing through the following sequential phases: i) sedation, ii) intoxication, possibly with involuntary
excitement, iii) anaesthesia, (iv) respiratory arrest and subsequent cardiac failure.
Pharmaceutical particulars
List of excipients
Tartrazine 1409 (E102) Glycerol
Industrial Methylated Spirit
Water for Injections
Major Incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life after first opening the immediate packaging: 28 days
Special precautions for storage
Do not store above 25ºC. Protect from light.
This product does not contain any antimicrobial preservative.
Following withdrawal of the first dose use within 28 days. Discard unused material.
Discard container if any sediment is observed,
Nature and composition of immediate packaging
100 ml, Amber, Type II glass vial with a centre-hole aluminium seal and a chlorobutyl rubber bung.
250 ml, Amber, Type II glass vial with a centre-hole aluminium seal and a chlorobutyl rubber bung.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused product must be destroyed in accordance with the Misuse of Drugs Regulations (2001).
Any waste material should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium
Marketing Authorisation Number
Vm 32742/4033
Significant changes
Date of the first authorisation or date of renewal
21 October 1993
Date of revision of the text
June 2018
Any other information
Legal category
Legal category: POM-V
GTIN
GTIN description:PENTOJECT 100ML
GTIN:5055037400045